Arrays designed to measure cytokine responses of different sides of the immune system

Logan, UT, April 25th, 2022 – Quansys Biosciences releases four new assays to measure cytokine responses of the human immune system. Each array is designed to measure cytokine responses of different aspects of the immune system including T cells, innate immunity, inflammation, and the type 2 immune response.

The four arrays encompass 20 biomarkers involved in immunology research, drug discovery, and clinical trials. The biomarkers include GMCSF, IFNα, IFNβ, IFNγ, IL-1α, IL-1β, IL-2, IL-4, IL-5, IL-6, IL-10, IL-12p70, IL-13, IL-15, IL-17a, IL-18, IL-21, IL-33, TNFα, and TNFβ. All 20 biomarkers are fully compatible and can be customized so that multiple arms of the immune system can be studied simultaneously.

Dysregulation of these different aspects of the immune system is involved in many different disease states such as allergy, autoimmune diseases, cancer, infectious diseases, and parasites.

Adam Brown, CEO of Quansys Biosciences, noted “The release of these four arrays represents our commitment to fighting for a disease-free world. At Quansys we recognize and appreciate the amount of research required to fight for a healthier world.”

About Quansys Biosciences

Quansys Biosciences is located in Logan, Utah and is focused on the mission to develop and manufacture superior assays, equipment, and software that accelerate the discovery, diagnostics, understanding, and treatment of disease.

For further information please contact:
Kent Nelson, Marketing Manager at info@quansysbio.com